357 related articles for article (PubMed ID: 30910864)
1. Personalizing Precision Oncology Clinical Trials in Latin America: An Expert Panel on Challenges and Opportunities.
Arai RJ; Guindalini RSC; Llera AS; O'Connor JM; Muller B; Lema M; Freitas HC; Soria T; Delgado L; Landaverde D; Montenegro P; Riechelmann RP
Oncologist; 2019 Aug; 24(8):e709-e719. PubMed ID: 30910864
[TBL] [Abstract][Full Text] [Related]
2. Globalization of clinical trials: Variation in estimated regional costs of pivotal trials, 2015-2016.
Qiao Y; Alexander GC; Moore TJ
Clin Trials; 2019 Jun; 16(3):329-333. PubMed ID: 30922113
[TBL] [Abstract][Full Text] [Related]
3. New clinical trial designs in the era of precision medicine: An overview of definitions, strengths, weaknesses, and current use in oncology.
Janiaud P; Serghiou S; Ioannidis JPA
Cancer Treat Rev; 2019 Feb; 73():20-30. PubMed ID: 30572165
[TBL] [Abstract][Full Text] [Related]
4. Precision medicine in pediatric oncology.
Forrest SJ; Geoerger B; Janeway KA
Curr Opin Pediatr; 2018 Feb; 30(1):17-24. PubMed ID: 29189430
[TBL] [Abstract][Full Text] [Related]
5. Overview of precision oncology trials: challenges and opportunities.
Fountzilas E; Tsimberidou AM
Expert Rev Clin Pharmacol; 2018 Aug; 11(8):797-804. PubMed ID: 30044653
[TBL] [Abstract][Full Text] [Related]
6. Precision oncology: A new era of cancer clinical trials.
Renfro LA; An MW; Mandrekar SJ
Cancer Lett; 2017 Feb; 387():121-126. PubMed ID: 26987624
[TBL] [Abstract][Full Text] [Related]
7. National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network.
Abrams J; Conley B; Mooney M; Zwiebel J; Chen A; Welch JJ; Takebe N; Malik S; McShane L; Korn E; Williams M; Staudt L; Doroshow J
Am Soc Clin Oncol Educ Book; 2014; ():71-6. PubMed ID: 24857062
[TBL] [Abstract][Full Text] [Related]
8. American Society of Clinical Oncology Developing First Clinical Trial.
Brower V
J Natl Cancer Inst; 2015 Nov; 107(11):djv356. PubMed ID: 26538625
[No Abstract] [Full Text] [Related]
9. Brazilian health-care policy for targeted oncology therapies and companion diagnostic testing.
Ferreira CG; Achatz MI; Ashton-Prolla P; Begnami MD; Marchini FK; Stefani SD
Lancet Oncol; 2016 Aug; 17(8):e363-e370. PubMed ID: 27511160
[TBL] [Abstract][Full Text] [Related]
10. An overview of the NCI precision medicine trials-NCI MATCH and MPACT.
Do K; O'Sullivan Coyne G; Chen AP
Chin Clin Oncol; 2015 Sep; 4(3):31. PubMed ID: 26408298
[TBL] [Abstract][Full Text] [Related]
11. Defining precision: The precision medicine initiative trials NCI-MPACT and NCI-MATCH.
Coyne GO; Takebe N; Chen AP
Curr Probl Cancer; 2017; 41(3):182-193. PubMed ID: 28372823
[TBL] [Abstract][Full Text] [Related]
12. Perspective on Precision Medicine in Oncology.
Johnson TM
Pharmacotherapy; 2017 Sep; 37(9):988-989. PubMed ID: 28632968
[TBL] [Abstract][Full Text] [Related]
13. Considerations of developing an NGS assay for clinical applications in precision oncology: The NCI-MATCH NGS assay experience.
Lih CJ; Takebe N
Curr Probl Cancer; 2017; 41(3):201-211. PubMed ID: 28625332
[TBL] [Abstract][Full Text] [Related]
14. Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial.
Rodon J; Soria JC; Berger R; Batist G; Tsimberidou A; Bresson C; Lee JJ; Rubin E; Onn A; Schilsky RL; Miller WH; Eggermont AM; Mendelsohn J; Lazar V; Kurzrock R
Ann Oncol; 2015 Aug; 26(8):1791-8. PubMed ID: 25908602
[TBL] [Abstract][Full Text] [Related]
15. Path toward Precision Oncology: Review of Targeted Therapy Studies and Tools to Aid in Defining "Actionability" of a Molecular Lesion and Patient Management Support.
Chae YK; Pan AP; Davis AA; Patel SP; Carneiro BA; Kurzrock R; Giles FJ
Mol Cancer Ther; 2017 Dec; 16(12):2645-2655. PubMed ID: 29203694
[TBL] [Abstract][Full Text] [Related]
16. Obstacles to precision oncology: confronting current factors affecting the successful introduction of biomarkers to the clinic.
Prudkin L; Nuciforo P
Cell Oncol (Dordr); 2015 Feb; 38(1):39-48. PubMed ID: 25185990
[TBL] [Abstract][Full Text] [Related]
17. Precision oncology: neither a silver bullet nor a dream.
Sánchez NS; Mills GB; Mills Shaw KR
Pharmacogenomics; 2017 Nov; 18(16):1525-1539. PubMed ID: 29061079
[TBL] [Abstract][Full Text] [Related]
18. Current-day precision oncology: from cancer prevention, screening, drug development, and treatment - have we fallen short of the promise?
Morgan G; Aftimos P; Awada A
Curr Opin Oncol; 2016 Sep; 28(5):441-6. PubMed ID: 27428363
[TBL] [Abstract][Full Text] [Related]
19. Genomic Alteration-Driven Clinical Trial Designs in Oncology.
Simon R
Ann Intern Med; 2016 Aug; 165(4):270-8. PubMed ID: 27214515
[TBL] [Abstract][Full Text] [Related]
20. Patient-centric trials for therapeutic development in precision oncology.
Biankin AV; Piantadosi S; Hollingsworth SJ
Nature; 2015 Oct; 526(7573):361-70. PubMed ID: 26469047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
